1 Introduction Antibody-drug conjugates (ADC) are an emerging technology that selectively targets cancer cells to overcome the limitations of chemotherapy.ADC binds to antigens, especially those overexpressed on the surface of cancer cells, reducing side effects caused by nonspecific targeting and improving the therapeutic index. The idealADC efficacy relies entirely on several physicochemical factors, such as … Read more
Antibody-drug conjugates (ADCs) consist of linker, payload, and monoclonal antibodies (mAb). They combine the advantages of high specificity targeting ability and potent cytotoxic effects, achieving precise and efficient destruction of cancer cells, making them one of the hot topics in anticancer drug development.Since the first ADC drug Mylotarg® (gemtuzumab ozogamicin) was approved by the FDA … Read more
Introduction The design of clinically successful ADCs depends not only on the potency of the payload and its attachment points, the stability of the linker, and effective drug release, but also on the choice of antibodies and bioconjugation technology. Over the past decade, all FDA-approved ADCs have existed in the form of heterogeneous mixtures of … Read more
Hello everyone, this week I am sharing an article published in JACS titled “Late-Stage Aromatic C–H Bond Functionalization for Cysteine/Selenocysteine Bioconjugation.” The corresponding authors are Professor Wang Binju from Xiamen University, Dr. Daphna Shimon from Hebrew University, and Professor Norman Metanis. Professor Wang’s research focuses on multiscale theoretical simulations of chemical reactions in aqueous solutions … Read more
–01– Introduction Antibody-drug conjugates (ADC) are known as “magic bullets” that precisely target tumor cells through antibodies, delivering cytotoxic drugs while combining the precision of targeted therapy with the potent killing power of chemotherapy. Over the past decade, ADCs have gradually matured in the treatment of solid tumors and hematological malignancies, becoming a revolutionary field … Read more
01 DAC‘s Emergence and Advantages Cancer therapeutics need to balance efficacy and safety, even targeted chemotherapy does not always only kill abnormal cancer cells, and non-specific toxicity can lead to a low therapeutic index and side effects. The technology of Proteolysis-targeting chimeras (PROTACs), which achieve therapeutic effects by promoting the degradation of target proteins, is … Read more
Introduction Antibody-drug conjugates (ADC) combine the high specificity of monoclonal antibodies with the high potency of small molecule cytotoxic drugs to enhance the targeting of cancer therapies and reduce side effects. Compared to traditional antibodies or antibody fragments, ADCs can release highly active cytotoxins within tumor tissues, theoretically leading to higher efficacy. ADCs have undergone … Read more
Antibody-drug conjugates (ADC) are a class of targeted cancer therapies that combine the high specificity of monoclonal antibodies with the potent activity of small molecule cytotoxic drugs to enhance tumor targeting and reduce side effects. Compared to traditional antibodies or antibody fragments, ADCs theoretically have higher efficacy due to their ability to release highly active … Read more
Preface Preface Author Cloud Assistant Antibody-drug conjugates (ADCs) are a class of emerging drugs that combine the advantages of both antibodies and small molecule toxins. Compared to traditional cytotoxic drugs, ADCs have the advantages of strong targeting and fewer side effects, making them promising in the field of tumor therapy. To date, 11 ADC drugs … Read more
ADC drug conjugation refers to the method of linking various components of ADC, which determines the drug-antibody conjugation ratio (DAR) and homogeneity, affecting the drug’s activity, tolerance, and stability. It is generally divided into random coupling and site-specific coupling. Non-Site-Specific Coupling Common methods include coupling at Lys residues and Cys residues. Site-Specific Coupling, which includes … Read more